<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329016</url>
  </required_header>
  <id_info>
    <org_study_id>820</org_study_id>
    <nct_id>NCT01329016</nct_id>
  </id_info>
  <brief_title>Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)</brief_title>
  <acronym>GDM</acronym>
  <official_title>Glyburide and Metformin for Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacokinetic and pharmacodynamic study evaluating glyburide, metformin, and
      combination treatment for gestational diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) is a common complication of pregnancy. Multiple treatment
      regimens are currently used for the management of GDM. Following failure of diet therapy,
      insulin, glyburide and metformin are all used in the treatment of GDM with the oral
      medications providing comparable outcomes with insulin but easier route of administration and
      schedule. The proposed work will evaluate the pharmacokinetics (PK) and pharmacodynamics (PD)
      of glyburide and metformin alone and in combination in order to lay the foundation in
      establishing dosage and response information that could be utilized in designing a phase III
      randomized trial that will ultimately evaluate GDM treatment optimization.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study drug dosage in pregnancy</measure>
    <time_frame>Completion of data collection (4-5mnths on average in GDM and healthy pregnant women and max of 6 months in newly diagnosed T2DMs)</time_frame>
    <description>(1) Determination of metformin dosage in pregnancy needed to produce comparable concentrations to the approved dosage range in non-pregnant women. (2)To compare metformin apparent oral clearance in pregnant and non-pregnant women. (3)To evaluate the effect of GLY monotherapy, MET monotherapy, and GLY-MET combination on insulin sensitivity, beta-cell responsivity index and disposition index (response vectors) describing the mechanism and magnitude of effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine GLY and MET PK parameters</measure>
    <time_frame>Conclusion of data collection (up to 6 months)</time_frame>
    <description>Determining GLY &amp; MET PK parameters, including AUC, max concentration, time to max &amp; min concentrations, oral clearance, half-life, oral volume of distribution, umbilical cord plasma concentrations; correlation between CYP2C9, CYP3A5, BCRP, OATP2B1 genotypes &amp; GLY PK/PD; GLY &amp; MET PD parameters, including derived parameters from PK/PD modeling for pregnant &amp; nonpregnant subjects; duration of initiation of treatment to glycemic control; effects of GDM &amp; glycemic control on maternal &amp; umbilical cord EPC cells &amp; sFLT concentrations; GLY &amp; MET half-life in neonates; efficacy &amp; safety data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GDM Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with GDM requiring treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-pregnant Type 2 Diabetes Milletus Subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Pregnant Women</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy pregnant women with normal 1-hour glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.</description>
    <arm_group_label>GDM Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.</description>
    <arm_group_label>GDM Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide-Metformin combination</intervention_name>
    <description>Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.</description>
    <arm_group_label>GDM Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Gestational Diabetes Subject Selection

          1. Pregnant women (singleton pregnancy)

          2. Gestational diabetes mellitus

          3. Able to give written informed consent

          4. Drug treatment is required for GDM

          5. Gestational age 20-32 weeks

               -  Gestational diabetes diagnosis must occur after 20 weeks and prior to 32 weeks
                  gestation

               -  Randomization and treatment initiation must occur no later than 32 weeks
                  gestation

          6. Willing to avoid ethanol

          7. 18-45 years of age

        Type 2 Diabetes Mellitus Subject Selection

          1. Able to give written informed consent

          2. New diagnosis of type 2 diabetes mellitus

          3. Plan to receive metformin for treatment of type 2 diabetes mellitus

          4. 18-45 years of age

          5. Female

          6. Negative pregnancy test

          7. Hemoglobin A1C &gt; 7%

        Healthy Pregnant Women

          1. Able to give written informed consent

          2. Pregnant women (singleton)

          3. Normal 1-hour glucose tolerance test

          4. 20-32 weeks gestation

          5. 18-45 years of age

        Neonates: All the infants of the pregnant women participating in this study will be
        included

        Exclusion Criteria:

        Women with GDM and T2DM

          1. Women taking medications expected to interact with glyburide, metformin or alter blood
             glucose concentrations

          2. Serum creatinine &gt; 1.2 mg/dL

          3. Hematocrit &lt; 28%

          4. Allergy to glyburide, metformin or sulfa

          5. Significant hepatic disease

          6. Congestive heart failure or history of MI

          7. Moderate to severe pulmonary disease

          8. Adrenal or pituitary insufficiency

        Healthy Pregnant Women

          1. Receiving any hypoglycemic agents

          2. Receiving corticosteroids

          3. Known kidney, liver, heart, pulmonary, adrenal or pituitary disease

          4. Hematocrit &lt; 28%

        Neonates

          1. Infants that are not viable or too ill for blood sample collection will be included
             for clinical outcomes data collection, but will be excluded from other research
             activities.

          2. Infants &lt; 1.5 kg will be included for clinical outcomes data collection, but will be
             excluded from blood sample collection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F. Hebert, PharmD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Caritis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary DV Hankins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Flockhart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Glyburide</keyword>
  <keyword>Metformin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

